Shares of Illumina, Inc. (NASDAQ:ILMN) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $222.32 and last traded at $214.86, with a volume of 218100 shares. The stock had previously closed at $215.35.
A number of brokerages have issued reports on ILMN. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $205.00 target price (up from $200.00) on shares of Illumina in a research note on Wednesday, October 25th. Barclays PLC reaffirmed an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a research note on Wednesday, August 9th. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a research note on Wednesday, August 2nd. Finally, BidaskClub downgraded Illumina from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. Illumina has a consensus rating of “Hold” and an average price target of $200.88.
The company has a market cap of $31,369.56, a PE ratio of 62.82, a price-to-earnings-growth ratio of 3.55 and a beta of 0.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million during the quarter, compared to the consensus estimate of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s revenue was up 17.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.97 EPS. analysts anticipate that Illumina, Inc. will post 3.75 EPS for the current fiscal year.
In other news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $205.71, for a total value of $29,827.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michel Bouchard sold 616 shares of Illumina stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $200.00, for a total value of $123,200.00. Following the completion of the transaction, the chief accounting officer now owns 15,161 shares of the company’s stock, valued at approximately $3,032,200. The disclosure for this sale can be found here. Insiders sold a total of 189,906 shares of company stock valued at $39,211,744 in the last quarter. Company insiders own 0.89% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Illumina by 2.6% during the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after purchasing an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Illumina by 3.1% during the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after purchasing an additional 76,452 shares during the last quarter. Capital World Investors lifted its stake in Illumina by 23.8% during the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in Illumina by 55.6% during the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC purchased a new stake in Illumina during the second quarter worth approximately $211,584,000. Hedge funds and other institutional investors own 90.76% of the company’s stock.
WARNING: This article was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://transcriptdaily.com/2017/11/27/illumina-inc-ilmn-hits-new-52-week-high-at-222-32.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.